GS
UTHR icon

GTS Securities’s United Therapeutics UTHR Stock Holding History

GTS Securities’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,700
Closed -$1.68M – 4001
2024
Q3 		$1.68M Sell
4,700
-1,200
-20% -$405K ﹤0.01% 1696
2024
Q2 		$1.88M Buy
5,900
+1,500
+34% +$397K ﹤0.01% 1545
2024
Q1 		$1.01M Sell
4,400
-5,400
-55% -$1.22M ﹤0.01% 1966
2023
Q4 		$2.15M Buy
9,800
+3,300
+51% +$761K ﹤0.01% 1602
2023
Q3 		$1.47M Buy
+6,500
New +$1.5M ﹤0.01% 1737

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

GTS Securities's UTHR Position: Q2 2025 in Review

GTS Securities sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 708 shares — an estimated $218K sold.

GTS Securities first reported a position in UTHR in Q4 2023 and held it in 4 quarters. The position peaked at $1.36M in Q2 2024. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • GTS Securities reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 708 United Therapeutics shares in Q2 2025, an estimated $218K.
  • GTS Securities first reported a position in United Therapeutics in Q4 2023 and held it in 4 quarters.
  • GTS Securities's United Therapeutics position peaked at $1.36M in Q2 2024.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.